Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
111,Inc., co-founded by Gang Yu and Junling Liu in 2010, is a leading digital and ...
111,Inc., co-founded by Gang Yu and Junling Liu...
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...
VBL Therapeutics is a publicly traded (NASDAQ: ...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committ...
Verastem Oncology (Nasdaq: VSTM) is a commercia...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.